StockData

Cosmos Health vs Cellyan Biotechnology

COSM and HKPD side by side, both in wholesale trade-non-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How COSM and HKPD compare

Cosmos Health grew revenue faster over the last twelve months (33.8% versus −33.9% for Cellyan Biotechnology).

Cellyan Biotechnology keeps more of each dollar of sales as profit, with a net margin of −8.5% compared with −33.1% at Cosmos Health.

Cosmos Health scores higher on the StockData Score (4 against 3 for Cellyan Biotechnology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCOSMHKPD
Size and price
Market cap$326M–
Share price$3.24$1.62
Change, 1 year−77.8%−93.4%
Change, 5 years−99.8%–
Beta (5Y)5.79–
Employees1632
StockData Score
Total score4 (better)3
Valuation score00
Growth score2 (better)0
Performance score01 (better)
Health score22
Dividend score00
Valuation
P/S4.4×–
P/B15.8×–
FCF yield−3.0%–
Fair value$1.38–
Margin of safety−135%–
Growth
Revenue growth (TTM)33.8% (better)−33.9%
Revenue growth, 5Y average3.3%–
Profitability
Gross margin10.3%10.3% (better)
Operating margin−24.9%−17.8% (better)
Net margin−33.1%−8.5% (better)
FCF margin−13.5%−5.9% (better)
Return on equity−104%−15.5% (better)
Return on invested capital−60.9%−22.5% (better)
Financial health
Debt / equity0.06 (better)0.09
Interest coverage−7.8× (better)−17.8×
Current ratio1.053.86 (better)
Altman Z-score1.81–
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield−2.6%–
Shareholder yield−2.6%–
Ownership
Held by institutions2.1%1.5%
Held by insiders17.4%81.9%
Insider net buying, 12 months$1.6M–
Short interest, % of float2.1%0.57%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.